CDK-mediated regulation of cell functions via c-jun phosphorylation and AP-1 activation

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Vanden Bush, Tony J ^a   Bishop, Gail A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; CD40 ANTIGEN; CDK4 PROTEIN, HUMAN; CDK4 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE; INTERLEUKIN 6; MEMBRANE PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TLR7 PROTEIN, HUMAN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL CYCLE; IMMUNE SYSTEM; METABOLISM; PHOSPHORYLATION;

ANIMALS; ANTIGENS, CD40; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MEMBRANE GLYCOPROTEINS; MICE; PHOSPHORYLATION; TOLL-LIKE RECEPTOR 7; TRANSCRIPTION FACTOR AP-1;

EID: 79955781017     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019468     Document Type: Article

References (48)

1. Sherr CJ, Roberts JM, (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
2. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P, (2003) Cdk2 knockout mice are viable. Curr Biol 13: 1775-1785.
3. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, et al. (1999) Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 19: 7011-7019.
4. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, et al. (1999) Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22: 44-52.
5. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, et al. (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35: 25-31.
6. Su TT, Stumpff J, (2004) Promiscuity rules? The dispensability of cyclin E and Cdk2. Sci STKE 2004: pe11.
7. Jirawatnotai S, Aziyu A, Osmundson EC, Moons DS, Zou X, et al. (2004) Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J Biol Chem 279: 51100-51106.
8. Park DS, Morris EJ, Padmanabhan J, Shelanski ML, Geller HM, et al. (1998) Cyclin-dependent kinases participate in death of neurons evoked by DNA-damaging agents. J Cell Biol 143: 457-467.
9. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, et al. (2006) Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 66: 7509-7515.
10. Liu L, Schwartz B, Tsubota Y, Raines E, Kiyokawa H, et al. (2008) Cyclin-dependent kinase inhibitors block leukocyte adhesion and migration. J Immunol 180: 1808-1817.
11. Besson A, Assoian RK, Roberts JM, (2004) Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer 4: 948-955.
12. Ip YT, Davis RJ, (1998) Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol 10: 205-219.
13. Kyriakis JM, (1999) Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Gene Expr 7: 217-231.
14. Karin M, (1996) The regulation of AP-1 activity by mitogen-activated protein kinases. Philos Trans R Soc Lond B Biol Sci 351: 127-134.
15. Hess J, Angel P, Schorpp-Kistner M, (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973.
16. Vanden Bush TJ, Bishop GA, (2008) TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur J Immunol 38: 400-409.
17. Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, et al. (2008) Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 180: 1954-1961.
18. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, et al. (2006) Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12: 1056-1064.
19. Nonomura Y, Nagasaka K, Hagiyama H, Sekine C, Nanki T, et al. (2006) Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and-independent pathways by cyclin-dependent kinase 4/6. Arthritis Rheum 54: 2074-2083.
20. Xie P, Hostager BS, Bishop GA, (2004) Requirement for TRAF3 in Signaling by LMP1 But Not CD40 in B Lymphocytes. J Exp Med 199: 661-671.
21. Eferl R, Wagner EF, (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
22. Morton S, Davis RJ, McLaren A, Cohen P, (2003) A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. Embo J 22: 3876-3886.
23. Besirli CG, Johnson EM Jr, (2003) JNK-independent activation of c-Jun during neuronal apoptosis induced by multiple DNA-damaging agents. J Biol Chem 278: 22357-22366.
24. Cho YY, Tang F, Yao K, Lu C, Zhu F, et al. (2009) Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res 69: 272-281.
25. Leopold P, O'Farrell PH, (1991) An evolutionarily conserved cyclin homolog from Drosophila rescues yeast deficient in G1 cyclins. Cell 66: 1207-1216.
26. Sherr CJ, Matsushime H, Roussel MF, (1992) Regulation of CYL/cyclin D genes by colony-stimulating factor 1. Ciba Found Symp 170: 209-219; discussion 219-226.
27. Solvason N, Wu WW, Parry D, Mahony D, Lam EW, et al. (2000) Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol 12: 631-638.
28. Mohamedali A, Soeiro I, Lea NC, Glassford J, Banerji L, et al. (2003) Cyclin D2 controls B cell progenitor numbers. J Leukoc Biol 74: 1139-1143.
29. Lane ME, Yu B, Rice A, Lipson KE, Liang C, et al. (2001) A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 61: 6170-6177.
30. Mahale S, Aubry C, Jenkins PR, Marechal JD, Sutcliffe MJ, et al. (2006) Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. Bioorg Chem 34: 287-297.
31. Thomas P, Smart TG, (2005) HEK293 cell line: a vehicle for the expression of recombinant proteins. J Pharmacol Toxicol Methods 51: 187-200.
32. Baccam M, Woo SY, Vinson C, Bishop GA, (2003) CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J Immunol 170: 3099-3108.
33. Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, et al. (2007) Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum 56: 1629-1637.
34. Galons H, Oumata N, Meijer L, (2010) Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat 20: 377-404.
35. Taylor PC, (2001) Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol 19: 153-168.
36. van den Berg WB, (2001) Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 3: 18-26.
37. Paul-Pletzer K, (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 42: 559-576.
38. Smolen JS, Maini RN, (2006) Interleukin-6: a new therapeutic target. Arthritis Res Ther 8 (Suppl 2): S5.
39. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, et al. (2009) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 15: 7144-7152.
40. Moses AM, Heriche JK, Durbin R, (2007) Clustering of phosphorylation site recognition motifs can be exploited to predict the targets of cyclin-dependent kinase. Genome Biol 8: R23.
41. Hostager BS, Bishop GA, (1999) Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 162: 6307-6311.
42. van den Heuvel S, Harlow E, (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054.
43. Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA, (2003) Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 278: 45382-45390.
44. Bishop GA, Ramirez LM, Waldschmidt TJ, (1994) Differential responses to Ig and class II-mediated signals in splenic B cell subsets from normal and autoimmune mice. Int Immunol 6: 1049-1059.
45. Kraus ZJ, Haring JS, Bishop GA, (2008) TNF receptor-associated factor 5 is required for optimal T cell expansion and survival in response to infection. J Immunol 181: 7800-7809.
46. Lehtonen A, Matikainen S, Miettinen M, Julkunen I, (2002) Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol 71: 511-519.
47. Benson RJ, Hostager BS, Bishop GA, (2006) Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K. Eur J Immunol 36: 2535-2543.
48. Krutzik PO, Nolan GP, (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70.